1591904-99-2

Upstream product

• 1591904-93-6 methyl (2,3,6-tri-O-benzyl-4-O-(2-naphthyl)methyl-α-D-glucopyranosyl)-(1→4)-(2-O-acetyl-6-O-tert-butyldiphenylsilyl-3-O-methyl-α-L-idopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside 
• 1591904-97-0 methyl (2,3,6-tri-O-benzyl-α-D-glucopyranosyl)-(1→4)-(2-O-acetyl-3-O-methyl-α-L-idopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside 
• 58479-61-1 tert-butylchlorodiphenylsilane 

Relevant academic research and scientific papers

New synthesis of idraparinux, the non-glycosaminoglycan analogue of the antithrombin-binding domain of heparin

Idraparinux, the fully O-sulfated, O-methylated, heparin-related pentasaccharide possessing selective factor Xa inhibitory activity, was prepared by a new synthetic pathway. This route was based on a [2+3] block synthesis utilizing a 6-O-silyl-protected l-idose-containing trisaccharide acceptor, which was glycosylated with a disaccharide donor containing a non-oxidized precursor of the glucuronic acid. The unique strategy of multiple functionalizations at pentasaccharide levels, involving triple methylation followed by oxidation of the glucose and the idose precursors into d-glucuronic and l-iduronic acids in one step, proved to be highly efficient, providing the target pentasaccharide through a 39-step synthesis starting from d-glucose and methyl α-d-glucopyranoside.